Recon: FDA approves Merck’s RSV antibody for infants; Gilead’s HIV combo studies placed on hold

• Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up (Reuters)
• Kennedy's firing of independent CDC advisers undermines vaccine confidence, experts say (Reuters)
• GOP senators zero in on Medicaid policy in Trump’s tax bill that has little impact on enrollment (STAT)
• Merck’s RSV antibody treatment for infants is approved by FDA (STAT)
• US FDA places clinical hold on Gilead trials testing HIV pill combination (Reuters)

• ‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe (Pink Sheet)
• Novo Nordisk starts new CagriSema weightloss drug trial (Reuters)
• The Quiet Voices Questioning China’s AI Hype (Bloomberg)
• Three Steps To Investor Heaven For Medtech Founders: Articulate, Explain, Clarify (MedTech Insight)
• EU plan would limit Chinese device makers in Europe (MedTech Dive)

• National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities (STAT)
• Avidity, FDA reach agreement on accelerated filing of rare disease drug (STAT)
• Hims & Hers says its weight-loss business can grow as US market changes (Reuters)
• GoodRx goes toe-to-toe with Hims, Ro as it pushes into ED treatment (Endpoints)
• Insmed's drug for rare lung disease meets main goal in mid-stage trial (Reuters)
• Exclusive: Rebooting dead human brains, a biotech startup seeks to reinvent early drug testing work (Endpoints)
• Exclusive: Scorpion spinout gets $177M for stealthy pipeline amid China competition (Endpoints)
• Former a16z biotech investment leader Vijay Pande exits the VC firm (Endpoints)
• Recursion to lay off 20% of staff, a month after slashing its pipeline (Endpoints)
• Odyssey pulls back from IPO plans as public markets remain frozen (Endpoints)

• AI In Health Delivery: Patients Most Confident When HCPs Are In Charge (MedTech Insight)
• Aneira Health Launches New Precision Medicine Platform Exclusively For Women (MedTech Insight)
• Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit (MedTech Insight)
• Elekta appoints Jakob Just-Bomholt as CEO (MedTech Dive)

• The Use of UV-C Light in Combination With Hydrogen Peroxide to Disinfect Packages in ESL and Aseptic Beverages (Food Safety)
• FDA cuts imperil food safety, but not how you might think (Science News)
• FDA warns food processors about Listeria, allergen and sanitation violations (Food Safety News)

• RFK Jr.’s chronic disease agency would eliminate or reduce funding for some prevention programs (STAT)
• We have ‘post-vaccination syndrome.’ We are tired of being used to score anti-vax points (STAT)
• Congressional report alleges organ procurement groups use loophole to boost ratings (STAT)
• HBCUs can help create a 21st-century bioeconomy and the talent pipeline it requires (STAT)
• US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings (Pink Sheet)
• HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse? (Pink Sheet)